Pyrotinib Improves Survival in Previously Treated HER2-Positive Metastatic Breast Cancer

In the phase III PHOEBE trial, treatment with pyrotinib plus capecitabine significantly improved overall survival compared with lapatinib plus capecitabine in patients with previously treated HER2-positive metastatic breast cancer.

Detalles Bibliográficos
Autor principal: Jacobson, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Conference Perspectives: Highlights from SABCS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8963278/
https://www.ncbi.nlm.nih.gov/pubmed/35348780
http://dx.doi.org/10.1093/oncolo/oyac013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8963278/
https://www.ncbi.nlm.nih.gov/pubmed/35348780
http://dx.doi.org/10.1093/oncolo/oyac013

Ejemplares similares